A clinical study conducted by the Royal Melbourne Hospital of a 20 year old man exhibiting symptoms of myocarditis upon the second administration of a COVID-19 mRNA vaccine concluded that given the scarcity of myocarditis, COVID-19 mRNA vaccine are still “overwhelmingly favourable for all age and sex groups, including young people.” The research team, led by Joshua Wong from the Royal Melbourne Hospital examined the patient who presented to the hospital with chest pain, fever, and sweats after his second dose of the Pfizer COVID-19 vaccine. Reportedly, 12 hours after receiving the second dose, the patient started experiencing symptoms of headaches, night sweats and chills and developed chest pain 48 hours later even though he was fine after his first dose 23 days prior. The patient had no history of myocarditis, however, an ultrasound of the heart showed a decrease in function of the left ventricles generally associated with myocarditis, …